CNTB
What one share of Connect Biopharma Holdings Limited holds
Pharmaceutical Preparations
Connect Biopharma, headquartered in San Diego, California, is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (“COPD”). The Company is advancing rademikibart, a next-generation, potentially best-in-class antibody designed to target interleukin-4-receptor alpha (“IL-4Rα”).
Connect Biopharma Holdings Limited’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.05 |
|---|---|
| Profit | −$1.19 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.05 |
| Cash and investments | $0.43 |
| Book value | $0.43 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$1.13 | $0.00 | −$0.87 | — | $1.84 |
| 2024 | — | −$0.28 | $0.01 | −$0.44 | — | $1.67 |
| 2025 | $0.00 | −$1.00 | $0.01 | −$0.93 | — | $0.74 |